2023
DOI: 10.1016/j.ejmech.2023.115383
|View full text |Cite
|
Sign up to set email alerts
|

Optimization of an α-aminonaphthylmethylphosphonic acid inhibitor of purple acid phosphatase using rational structure-based design approaches

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 83 publications
0
2
0
Order By: Relevance
“…A growing number of members of the large family of binuclear metallohydrolases have also emerged as targets for chemotherapeutics to treat a diverse range of human disorders 89 . Specifically, elevated levels of PAP activity in osteoclasts are indicative of an osteoporotic phenotype and consequently human PAP is a current target for the development of novel drugs to treat osteoporosis 89 , 90 . Using a combination of fragment-based screening and rational design inhibitors for PAP have been developed with inhibition constants in the nM range 89 , 90 .…”
Section: Applications Of Acid Phosphatasesmentioning
confidence: 99%
See 1 more Smart Citation
“…A growing number of members of the large family of binuclear metallohydrolases have also emerged as targets for chemotherapeutics to treat a diverse range of human disorders 89 . Specifically, elevated levels of PAP activity in osteoclasts are indicative of an osteoporotic phenotype and consequently human PAP is a current target for the development of novel drugs to treat osteoporosis 89 , 90 . Using a combination of fragment-based screening and rational design inhibitors for PAP have been developed with inhibition constants in the nM range 89 , 90 .…”
Section: Applications Of Acid Phosphatasesmentioning
confidence: 99%
“…Specifically, elevated levels of PAP activity in osteoclasts are indicative of an osteoporotic phenotype and consequently human PAP is a current target for the development of novel drugs to treat osteoporosis 89 , 90 . Using a combination of fragment-based screening and rational design inhibitors for PAP have been developed with inhibition constants in the nM range 89 , 90 . These inhibitors are selective for the active site of PAPs but are not yet soluble enough to be considered as suitable drug leads.…”
Section: Applications Of Acid Phosphatasesmentioning
confidence: 99%